Study summary

The purpose of this study is to evaluate response rate, survival, safety and tolerability of YM155 given in combination with rituximab in subjects with Non-Hodgkin’s Lymphoma.

Additional Study Details

Phase
Phase 2
Product
N/A
Product
YM155
Type
Interventional
Masking
None (Open Label)
Enrollment number
43
Show Additional Study Details

Get more information

Would you like more information about clinical trial sites that are recruiting participants for A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment? Contact us by filling out your information to the right and we’ll respond to you.

  • A caregiver
  • A healthcare provider
  • A parent
  • A patient
  • A patient advocate
  • Algeria
  • Argentina
  • Armenia
  • Australia
  • Austria
  • Belarus
  • Belgium
  • Bosnia And Herzegovina
  • Brazil
  • Bulgaria
  • Canada
  • Chile
  • China
  • Colombia
  • Croatia
  • Czech Republic
  • Denmark
  • Dominican Republic
  • Egypt
  • Estonia
  • Finland
  • Former Serbia and Montenegro
  • France
  • Georgia
  • Germany
  • Greece
  • Guatemala
  • Hong Kong
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Ireland
  • Israel
  • Italy
  • Japan
  • Jordan
  • Kazakhstan
  • Latvia
  • Lebanon
  • Lithuania
  • Macedonia
  • Malaysia
  • Mexico
  • Montenegro
  • Morocco
  • Netherlands
  • New Zealand
  • Norway
  • Panama
  • Peru
  • Philippines
  • Poland
  • Portugal
  • Puerto Rico
  • Republic of Korea
  • Republic of Moldova
  • Romania
  • Russian Federation
  • Saudi Arabia
  • Serbia
  • Singapore
  • Slovakia
  • Slovenia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Taiwan, Province of China
  • Thailand
  • Turkey
  • Ukraine
  • United Kingdom
  • United States
  • Vietnam

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

    Locations

    Contact Us
    Contact Us
    Withdrawn
    Site US810 University of Alabama at Birmingham
    Birmingham, AL, United States, 35294-3300
    Withdrawn
    Site US1895 Tower Cancer Research Foundation
    Beverly Hills, California, United States, 90211-1850
    Withdrawn
    Site US46 Washington Cancer Institute (MedStar Research Institute)
    Washington DC, DC, United States, 20010
    Withdrawn
    Site US2815 American Clinical Trials
    Pembroke Pines, FL, United States, 33028
    Completed
    Site US2778 John B. Amos Cancer Center
    Columbus, GA, United States, 31904
    Withdrawn
    Site US50 Rush University Medical Center
    Chicago, Illinois, United States, 60612
    Completed
    Site US55 Loyola University Hospital - Maywood
    Maywood, IL, United States, 60153
    Withdrawn
    Site US419 Louisiana State University School of Medicine
    Shreveport, Louisiana, United States, 71103
    Withdrawn
    Site US516 National Cancer Institute
    Bethesda, MD, United States, 20892-1457
    Withdrawn
    Site US667 Washington University School of Medicine
    St. Louis, Mo, United States, 63110
    Completed
    Site US9 Mount Sinai School of Medicine
    New York, New York, United States, 10029
    Completed
    Site US2802 Mecklenburg Medical Group
    Charlotte, NC, United States, 28204
    Completed
    Site US2149 Gabrail Cancer Center Research
    Canton, Ohio, United States, 44718
    Withdrawn
    Site US1996 Providence Portland Medical Center
    Portland, Oregon, United States, 97213
    Withdrawn
    Site US960 Fox Chase Cancer Center
    Philadelphia, PA, United States, 19111
    Withdrawn
    Site US58 Medical Center for the University of South Carolina
    Charleston, SC, United States, 29425
    Completed
    Site US402 University of Texas Health Science Center - San Antonio
    San Antonio, TX, United States, 78229
    Withdrawn
    Site FR2701 CH de Blois
    Blois, France, 41150
    Completed
    Site FR1926 Institut Bergonie
    Bordeaux-cedex, France, 33076
    Withdrawn
    Site FR2625 Centre Hospitalier de Cannes
    Cannes, France, 6400
    Withdrawn
    Site FR2814 CHU Nantes Service hématologie Clinique
    Nantes, France, 44093
    Withdrawn
    Site FR1896 CHU Nice
    Nice, France, 6200
    Completed
    Site FR2700 Centre Antoine Lacassagne
    Nice, France, 06189
    Completed
    Site FR476 Hopital Saint Louis
    Paris, France, 75475
    Withdrawn
    Site FR1920 CHU de Poitiers
    Poitiers, France, 86021
    Completed
    Site FR1889 Centre de Lutte Contre le Cancer - Centre Henri Becquerel
    Rouen, France, 76038
    Completed
    Site FR1897 Hopital Bretonneau
    Tours, France, 37044
    Withdrawn
    Site FR2571 Hopitaux de Brabois
    Vandoeuvre, France, 54550
    Completed
    Site ES1349 Hospital del Mar
    Barcelona, Spain, 08003
    Completed
    Site ES1339 Hospital Universitario Ramon y Cajal
    Madrid, Spain, 28034
    Withdrawn
    Site ES1350 Hospital Universitario de la Princesa
    Madrid, Spain, 28006
    Completed
    Site ES1346 Hospital Universitario de Salamanca
    Salamanca, Spain, 37007
    Completed
    Site GB2702 Addenbrookes Hospital
    Cambridge, United Kingdom, CB2 0QQ
    Completed
    Site GB1928 St. Georges Hospital
    London, United Kingdom, SW17 0QT
    Completed
    Site GB2624 The Christie NHS Foundation Trust
    Manchester, United Kingdom, M20 4BX
    Withdrawn
    Site GB2012 Nottingham City Hospital
    Nottingham, United Kingdom, NG5 1PB
    Completed
    Site GB1903 Oxford Radcliffe Hospital
    Oxford, United Kingdom, OX3 7LJ
    Withdrawn
    Site ES1344 Hospital Universitario Vall D'Hebron
    Barcelona, Spain, 08035
    Completed
    Site ES2967 Hosptial Universitario Madrid Sanchinarro
    Madrid, Spain, 28050
    Withdrawn
    Site US2879 Yale University School of Medicine
    New Haven, CT, United States, 06520

    Frequently Asked Questions

    Are clinical trials only for people with advanced cancer?

    While some clinical trials may focus on more advanced cancers, many trials are open to patients at various stages of their cancer. Each study has rules about who can take part. For example, only patients in a certain age group or those who have a certain type of tumor may be able to join.

    Will I have to stop my current treatment to participate in a clinical trial?

    Sometimes researchers want participants to keep taking their current treatments during a clinical trial. Other times, you may need to stop your current treatments for a while. If the investigational treatment doesn't work, you can usually go back to your original treatment plan.

    Should I be worried about getting a placebo?

    In cancer clinical trials, a placebo is only used if there is no other treatment for that type of cancer. This helps compare an investigational treatment to the placebo. Placebos are rarely used in cancer trials because the best available treatment, called the “standard of care”, is usually given instead.

    Do I need a referral from my doctor to take part in a study?

    Your doctor may not know about all the opportunities for clinical trials that are available to you. Talk to your doctor or other medical provider about clinical trial information that you find. They can help you decide if a clinical trial is right for you. If you do not find any options on this website, we recommend you visit an online public registry website like clinicaltrials.gov to see a wide variety of available clinical trials.

    Explore More

    1

    What are clinical trials?

    2

    Why are Clinical Trials Important?

    3

    Why Participate in a Clinical Trial?